Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business
Biosimilars Still Seen As Key Growth Driver Despite Q1 Sales Decline
During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.
